Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.
We report our experience with isolated hepatic perfusion (IHP) with tumor necrosis factor (TNF) and melphalan in an experimental pig study and of a phase I study in humans. IHP was performed with inflow catheters in the hepatic artery and portal vein and an outflow catheter in eh caval vein. An extracorporeal venovenous bypass was used. IHP consisted of a 60-min perfusion with hyperthermia (> 41 degrees C). For the pig protocol rhTNF alpha 50 micrograms/kg alone (n = 5) or rhTNF alpha 50 micrograms/kg plus melphalan 1 mg/kg (n = 3) were added. In two control pigs no drugs were added. In the phase I study, patients received melphalan 1 mg/kg with 0.4 mg rhTNF alpha (n = 8) or 0.8 mg rhTNF alpha (n = 1). After the perfusion the liver was washed with Macrodex before vascular continuity was restored. All pigs but one survived the procedure. Systemic leakage was less than 0.02%. Transient, mild liver toxicity was seen in all pigs, including controls, as demonstrated by liver enzyme assays and histology. There was no significant hemodynamic, cardiopulmonary hematological, or renal toxicity. In the phase I clinical study there was leakage in one patient (cumulative leakage 20%). There were three perioperative deaths (one possibly drug-related). All patients demonstrated significant hepatotoxicity. Survival ranged from 6 to 26 months (median 10.3 months). All patients demonstrated a tumor response (partial response 5/6, 1/6 stable disease) with a median duration of 18 weeks. In contrast to our pig program, many problems were encountered in the phase I study. By using both the hepatic artery and portal vein for IHP we encountered more toxicity than expected based on data from the pig program, resulting in fatal coagulative disturbances in one patient who received the second rhTNF alpha dose. Furthermore, local control after one IHP with TNF alpha and melphalan is only temporary.
de Vries
M R
MR
Department of Surgical Oncology, Dr. Daniël den Hoed Cancer Center, University of Hospital Rotterdam, The Netherlands.
Borel Rinkes
I H
IH
van de Velde
C J
CJ
Wiggers
T
T
Tollenaar
R A
RA
Kuppen
P J
PJ
Vahrmeijer
A L
AL
Eggermont
A M
AM
D000209:Acute-Phase Proteins / Q000378:metabolism; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000473:pathology*; D006801:Humans; D007378:Interleukins / Q000378:metabolism; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use; D010477:Perfusion; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D012995:Solubility; D015996:Survival Rate; D013552:Swine; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use
D000209:Acute-Phase Proteins; D018906:Antineoplastic Agents, Alkylating; D007378:Interleukins; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan